Encouraging Results with First-In-Class Targeted Therapy in Essential Thrombocythemia
Myeloproliferative Neoplasms (MPNs)
EHA/ICML 2025
Related content
Head and Neck Cancer
Overall survival of recurrent/metastatic head & neck squamous cell carcinoma patients progressing after ≥ 1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsulation-based immunotherapy: results of SAKK 11/16, a phase IIa trial
Exp Hematol Oncol
Fernandez E, Vernet R, Urwyler M, Von Rohr O, Charrier E, Belkouch MC, Saingier V, Courtout F, DeVito C, Ancrenaz V, Dulguerov N, Karenovics W, Grogg J, Renaux J, Gobat K, Müller G, Brezina T, Rordorf T, Joerger M, Michielin O, Villard J, Mach N
doi: 10.1186/s40164-025-00703-x
Lung, Respiratory and Thoracic Cancer
Treatment sequences in BRAF-V600-mutated non-small cell lung cancer: First-line targeted therapy versus first-line (chemo-) immunotherapy
J Thorac Oncol
Wiesweg M, Alaffas A, Rasokat A, Saalfeld FC, Rost M, Assmann C, Herster F, Hilbrandt M, Griesinger F, Kron A, Roeper J, Glanemann F, Kropf-Sanchen C, Reck M, Kulhavy J, Stenzinger A, Wolf J, Sebastian M, Schuler M, Wermke M, Frost N, Kopp HG, Christopoulos P, Scheffler M
doi: 10.1016/j.jtho.2025.04.016
Gastrointestinal Cancer
Molecular hyperselection for optimal choice of first-line targeted therapy independent of primary tumor sidedness: An exploratory analysis of the randomized FIRE-3 study performed in RAS wild-type metastatic colorectal cancer
Eur J Cancer
Weiss L, Stintzing S, Stahler A, Benedikt Westphalen C, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller CA, Kahl C, Seipelt G, Kullmann F, Heinrich K, Holch JW, Alig A, Jung A, Modest DP, Heinemann V
doi: 10.1016/j.ejca.2025.115399
RECOMMENDED
Breast Cancer
Compression therapy with surgical gloves compared to cold therapy with frozen gloves in preventing paclitaxel-induced peripheral neuropathy: Results from the prospective ELEGANT trial in patients with breast cancer
★ 1
Recommended by
Dr Andreas Müller, Faculty Member
★ 2
Recommended by
Prof. Dr Beat Thürlimann, Faculty Member
Eur J Cancer
Hanvic B, Joureau-Chabert A, Ouldbey Y, Toussaint P, Chanel E, Blanc E, Heudel P, Montagnier V, Pérol D, Bachelot T
doi: 10.1016/j.ejca.2025.115791
CHICAGO 2025
Lung, Respiratory and Thoracic Cancer
IMforte: Adding lurbinectedin to atezolizumab improves PFS and OS as first-line maintenance therapy in patients with ES-SCLC
Genitourinary Cancer
First-Line Therapy For Advanced Non-Clear Cell Renal Cell Carcinoma: A Systematic Review and Meta-Analysis
JAMA Oncol
Petrelli F, Verri E, Ghidini A, Vavassori I, Lonati V, Nolè F, Dottorini L
doi: 10.1001/jamaoncol.2025.1891
COMMENTED
Breast Cancer
Health-related quality of life with first- vs second-line CDK4/6 inhibitor use in advanced breast cancer: results from the SONIA trial
★ 1
Recommended and commented by
Dr Andreas Müller, Faculty Member
J Natl Cancer Inst
Wortelboer N, Kent S, Blommestein HM, van Ommen-Nijhof A, van der Noort V, van den Pol E, Páez CG, Beeker A, Beelen K, Hamming LC, Heijns JB, Honkoop AH, de Jong PC, van Rossum-Schornagel QC, van de Mheen CVS, Tol J, Driel CST, Vrijaldenhoven S, van Leeuwen-Stok AE, Sonke GS, Jager A, Konings IR
doi: 10.1093/jnci/djaf334
Lung, Respiratory and Thoracic Cancer
Phase III meta-analysis of first-line chemo-immunotherapy in ES-SCLC: Survival benefit without detectable class-level differences
Lung Cancer
Lamberti G, Andrini E, Zappi A, Di Odoardo A, Formelli MG, Campana D
doi: 10.1016/j.lungcan.2026.109376
Lung, Respiratory and Thoracic Cancer
Efficacy and safety of targeted therapy combined with anti-angiogenesis treatment in brain metastases of non-small cell lung cancer: a systematic review and meta-analysis
Lung Cancer
Pan Y, Gu Q
doi: 10.1016/j.lungcan.2025.108532